伊沃西尼

Description

ivosidenib · CAS 1448347-49-6 · C28H22ClF3N6O3. UNII Q2PCN8MAM6. Solubility: <1 mg/mL.

Identification

CAS Registry Number	1448347-49-6
PubChem CID	71657455
Molecular formula	C28H22ClF3N6O3
IUPAC name	(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyano-2-pyridinyl)-N-(5-fluoro-3-pyridinyl)-5-oxopyrrolidine-2-carboxamide
UNII (FDA)	Q2PCN8MAM6

Computed Descriptors

Molecular Weight	583.0
XLogP3	3.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	7
Exact Mass	582.1394008
Monoisotopic Mass	582.1394008
Topological Polar Surface Area	119
Heavy Atom Count	41
Formal Charge	0

Physical & Chemical Properties

Solubility	<1 mg/mL

Physical description & handling notes

• Ivosidenib is an antineoplastic agent that is effective in cancers with a susceptible IDH1 mutation, which indicates increased levels of oncometabolite D-2-hydroxyglutarate (D-2HG) in cancer cells. Ivosidenib decreases D-2HG levels in a dose-dependent manner by inhibiting the IDH1 enzyme. Ivosidenib inhibits both the mutant and wild-type IDH1 but does not inhibit IDH2.

GHS Hazard Classification

Reported hazard statements	H302 (50%), H360 (50%), H361 (25%), H372 (25%), H373 (50%)

Documented Uses

• Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor approved for use in the US and Europe. It is indicated for the treatment of patients with a susceptible IDH1 mutation with: - **Newly Diagnosed Acute Myeloid Leukemia (AML)** in combination [azacitidine] or as monotherapy for the treatment of newly diagnosed AML in adults who have comorbidities that preclude the use of intensive induction chemotherapy. this indication is reserved for adults 75 years or older in the US. - **Relapsed or refractory AML** in
• Ivosidenib is an orally available small molecule inhibitor of mutated isocitrate dehydrogenase-1 that is used as an antineoplastic agent in the treatment of adults of acute myelogenous leukemia (AML). Ivosidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Isocitrate Dehydrogenase Inhibitors
• Ivosidenib is approved to treat adults whose cancer has a certain mutation in the IDH1 gene, including:
• • Acute myeloid leukemia (AML). It is used:
• • Alone or with azacitidine in patients with newly-diagnosed cancer who are 75 years or older or who cannot receive intensiveinduction chemotherapy due to health problems.

Synonyms

Ivosidenib; 1448347-49-6; Tibsovo; AG-120; AG120; Q2PCN8MAM6; ivosidenibum; CHEBI:145430; DTXSID801027928; RefChem:57058; L01XX62; DTXCID801513494; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; RG120

Frequently Asked Questions

What are the CAS number and molecular formula of ivosidenib?

CAS 1448347-49-6; molecular formula C28H22ClF3N6O3; molecular weight — g/mol.

What other names is ivosidenib known by?

Ivosidenib, 1448347-49-6, Tibsovo, AG-120, AG120, Q2PCN8MAM6.

Is ivosidenib classified as hazardous?

Hazard statements reported: H302, H360, H361, H372, H373.

What are the key physical properties of ivosidenib?

Solubility: <1 mg/mL.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.